MX372775B - Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. - Google Patents

Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.

Info

Publication number
MX372775B
MX372775B MX2015013173A MX2015013173A MX372775B MX 372775 B MX372775 B MX 372775B MX 2015013173 A MX2015013173 A MX 2015013173A MX 2015013173 A MX2015013173 A MX 2015013173A MX 372775 B MX372775 B MX 372775B
Authority
MX
Mexico
Prior art keywords
methods
cell
cftr
chronic obstructive
obstructive pulmonary
Prior art date
Application number
MX2015013173A
Other languages
English (en)
Other versions
MX2015013173A (es
Inventor
Erik Schwiebert
Hongwu Gao
John Dixon
John Streiff
Original Assignee
Discoverybiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discoverybiomed Inc filed Critical Discoverybiomed Inc
Publication of MX2015013173A publication Critical patent/MX2015013173A/es
Publication of MX372775B publication Critical patent/MX372775B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos correctores de CFTR novedosos que son eficaces para recuperar el eflujo de haluro, procesar la proteína delF508-CFTR y transportar los iones de cloruro funcionales en una célula. También se proporcionan métodos para tratar los trastornos de plegamiento de proteínas (por ejemplo, fibrosis quística y enfermedad pulmonar obstructiva crónica). Los métodos incluyen administrar un compuesto corrector de CFTR o una sal o profármaco farmacéuticamente aceptable de este. En la presente también se proporcionan métodos para recuperar el eflujo de haluro en una célula, corregir un defecto de procesamiento de una proteína delF508- CEFTR en una célula y corregir los canales de cloruro de deIF508-CFTR funcional en una célula.
MX2015013173A 2013-03-15 2014-03-14 Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. MX372775B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788353P 2013-03-15 2013-03-15
PCT/US2014/027079 WO2014152213A2 (en) 2013-03-15 2014-03-14 Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Publications (2)

Publication Number Publication Date
MX2015013173A MX2015013173A (es) 2016-04-04
MX372775B true MX372775B (es) 2020-06-29

Family

ID=51581684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013173A MX372775B (es) 2013-03-15 2014-03-14 Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.

Country Status (9)

Country Link
US (1) US9815825B2 (es)
EP (1) EP2970248B1 (es)
JP (1) JP6514680B2 (es)
KR (1) KR20150131309A (es)
CN (1) CN105121437B (es)
AU (1) AU2014240026B2 (es)
CA (1) CA2903103C (es)
MX (1) MX372775B (es)
WO (1) WO2014152213A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2836463A1 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
WO2014081821A2 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small Molecule Bicyclic and Tricyclic CFTR Correctors
AU2013348018A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
CN105246887B (zh) * 2013-03-15 2018-05-11 发现生物医药公司 香豆素衍生物以及用于治疗过度增生性疾病的方法
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA3041675A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
AU2017348186A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating CFTR
MA49061A (fr) 2017-04-28 2021-04-21 Proteostasis Therapeutics Inc Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
US20210369749A1 (en) 2017-10-06 2021-12-02 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2019136314A1 (en) 2018-01-05 2019-07-11 The Curators Of The University Of Missouri Compounds and methods for treatment of cystic fibrosis
JP7560011B2 (ja) 2018-09-09 2024-10-02 カナートファーマ アーゲー 脳血管状態を治療するためのｃｆｔｒモジュレーターの使用
CN110156761B (zh) * 2019-06-18 2022-08-09 郑州大学 含香豆素-联苯骨架化合物、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566580A (en) * 1978-11-11 1980-05-20 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation and antiallergic agent containing the same as effective component
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003245935A1 (en) 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
KR20070084067A (ko) 2004-10-13 2007-08-24 와이어쓰 Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CN101351208A (zh) * 2005-11-01 2009-01-21 康乃尔研究基金会有限公司 减少细胞胆固醇水平和/或治疗或预防磷脂质病
US20090012148A1 (en) * 2005-11-01 2009-01-08 Maxfield Frederick R Reducing cellular cholesterol levels and/or treating or preventing phospholipidosis
EP2581451B1 (en) * 2007-12-13 2016-03-09 Indiana University Research and Technology Corporation Compounds for inhibiting mammalian s-nitrosoglutathione reductase
EP2411529A4 (en) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF BIOSYNTHESIS OF N-BOUND GLYCANS
ITMI20111068A1 (it) * 2011-06-14 2012-12-15 Azienda Ospedaliera Universitaria I Ntegrata Di Ve Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
CN105246887B (zh) 2013-03-15 2018-05-11 发现生物医药公司 香豆素衍生物以及用于治疗过度增生性疾病的方法
CA2903103C (en) 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders

Also Published As

Publication number Publication date
KR20150131309A (ko) 2015-11-24
AU2014240026B2 (en) 2018-06-14
HK1218420A1 (en) 2017-02-17
CN105121437A (zh) 2015-12-02
CA2903103A1 (en) 2014-09-25
AU2014240026A1 (en) 2015-08-20
US9815825B2 (en) 2017-11-14
WO2014152213A3 (en) 2014-11-13
MX2015013173A (es) 2016-04-04
JP2016515131A (ja) 2016-05-26
WO2014152213A2 (en) 2014-09-25
CA2903103C (en) 2020-06-09
EP2970248A4 (en) 2017-01-11
JP6514680B2 (ja) 2019-05-15
EP2970248A2 (en) 2016-01-20
CN105121437B (zh) 2018-12-04
EP2970248B1 (en) 2020-04-22
US20160024065A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
MX372775B (es) Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas.
WO2014081821A3 (en) Small Molecule Bicyclic and Tricyclic CFTR Correctors
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
MX374537B (es) Tricíclicos sustituidos y método para usarlos.
CY1122292T1 (el) Ενωσεις και μεθοδοι για αντιϊικη αγωγη
CY1118823T1 (el) Παραγωγα πυριδινης και πυραζινης για την θεραπευτικη αντιμετωπιση της χρονιας αποφρακτικης πνευμονοπαθειας
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX389354B (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
MX2018013002A (es) Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
HK1217092A1 (zh) 治疗性化合物及其用途
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201692298A1 (ru) Производные карбоксамидов
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин

Legal Events

Date Code Title Description
FG Grant or registration